## STE: STERIS plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.4% below STRENGTH zone (4.0-10.0%); PEG 1.75 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($248.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. 1,135 Shares in STERIS plc $STE Acquired by Legacy Capital Wealth Partners LLC**
- Source: MarketBeat | 20251202T120155 | Somewhat-Bullish | Relevance: 100%
- Legacy Capital Wealth Partners LLC acquired a new stake of 1,135 shares in STERIS plc (NYSE:STE) during the second quarter, valued at approximately $273,000. This comes as other institutional investors also adjusted their holdings, with Norges Bank making a significant new investment of $289.1 million. STERIS reported strong Q2 earnings, beating analyst expectations for both EPS and revenue, and announced a quarterly dividend of $0.63 per share.

**2. Norges Bank Buys Shares of 1,203,612 STERIS plc $STE**
- Source: MarketBeat | 20251202T113259 | Bullish | Relevance: 100%
- Norges Bank acquired 1,203,612 shares of STERIS plc (NYSE:STE) in Q2, valuing its stake at approximately $289.1 million and bringing its total ownership to about 1.22%. This comes as STERIS reported strong Q results, beating EPS and revenue estimates, and provided positive FY2026 guidance. Analyst sentiment for STERIS has improved, with a "Moderate Buy" consensus and an average target price of $273.50.

**3. Korea Investment CORP Has $11.49 Million Holdings in STERIS plc $STE**
- Source: MarketBeat | 20251202T111050 | Somewhat-Bullish | Relevance: 100%
- Korea Investment CORP decreased its stake in STERIS plc by 37.1% during the second quarter, now holding 47,830 shares valued at $11.49 million. STERIS reported strong Q2 earnings and issued positive FY2026 guidance, while analysts maintain a "Moderate Buy" rating with a $273.50 target price. The company also declared a quarterly dividend of $0.63 per share, and insiders have sold approximately $6.62 million worth of shares in the past 90 days.

**4. Choreo LLC Sells 3,076 Shares of STERIS plc $STE**
- Source: MarketBeat | 20251201T093342 | Somewhat-Bullish | Relevance: 100%
- Choreo LLC reduced its stake in STERIS plc by 47.7%, selling 3,076 shares and leaving them with 3,369 shares valued at approximately $809,000. STERIS plc reported strong quarterly earnings, beating analyst estimates with EPS of $2.47 and revenue of $1.46 billion, and provided positive FY2026 EPS guidance. Institutional investors hold a significant 94.69% of the company, while insiders have recently sold a substantial number of shares.

**5. Zacks Research Issues Negative Forecast for STERIS Earnings**
- Source: MarketBeat | 20251201T063333 | Neutral | Relevance: 100%
- Zacks Research has lowered its Q3 2026 EPS estimate for STERIS to $2.53 and projects FY2026 EPS of $10.20, while providing forecasts through Q1 2028. Despite this, STERIS recently beat earnings expectations with $2.47 EPS and $1.46B revenue, reiterating its FY2026 guidance. The report also highlights notable insider selling and details past analyst ratings and stock performance metrics.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.9% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.75 elevated, pricing in significant growth expectations. Forward P/E 23.3x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.2B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.75 |
| Forward P/E | 23.3 |
| Current P/E | 25.4 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.6% to -2.4% (-5.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.3pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.63), momentum weakening. RSI neutral at 54. OFD pattern: -DLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.35% (CS: 27) | Weak |
| RSI_14 | 54.2 | Neutral |
| MACD Histogram | -0.63 | Bearish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 1.042x | Above |
| vs SMA200 | 1.093x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $259.40
- **Stop Loss:** $248.90 (4.0% risk)
- **Target:** $269.90 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 90
- **Position Value:** $23,346.00
- **Portfolio %:** 23.35%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*